Karagun Barbaros S, Akbas Tugana, Arpaci Taner, Antmen Bulent
Department of Pediatric Hematology/Oncology, and Bone Marrow Transplantation Unit.
Department of Radiology Unit, Faculty of Medicine, Acibadem University, Adana Hospital, Adana, Turkey.
J Pediatr Hematol Oncol. 2018 Jan;40(1):71-73. doi: 10.1097/MPH.0000000000000870.
FK506 (tacrolimus) is an immunosuppressive drug and more potent than cyclosporine. FK506 is widely used for immunosuppression in the prevention and treatment of graft-versus-host disease after allogeneic bone marrow transplantation and solid organ transplantation. Neurotoxicity is a recognized complication of FK506 therapy, but ptosis and weakness of eye abduction unilaterally has not been reported in association with FK506 administration to date. We discuss a 13-year-old male patient who developed ptosis and weakness of eye abduction unilaterally 90 days after transplantation with bone marrow from an unrelated donor, for acute lymphoblastic leukemia in this case report. FK506 therapy was administered for graft-versus-host disease prophylaxis and CMV infection was treated with ganciclovir. The physical examination findings completely resolved 72 to 96 hours after concomitant FK506 and ganciclovir treatment were terminated.
FK506（他克莫司）是一种免疫抑制药物，比环孢素的效力更强。FK506广泛用于免疫抑制，以预防和治疗异基因骨髓移植和实体器官移植后的移植物抗宿主病。神经毒性是FK506治疗公认的并发症，但迄今为止，尚未有单侧上睑下垂和眼球外展无力与使用FK506相关的报道。在本病例报告中，我们讨论了一名13岁男性患者，他在接受无关供体的骨髓移植以治疗急性淋巴细胞白血病90天后，出现了单侧上睑下垂和眼球外展无力。给予FK506治疗以预防移植物抗宿主病，并用更昔洛韦治疗巨细胞病毒感染。在同时停用FK506和更昔洛韦治疗72至96小时后，体格检查结果完全消失。
